SECUKINUMAB SHOWS HIGHER SYMPTOMATIC IMPROVEMENT VERSUS INFLIXIMAB IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 1 YEAR ASSESSED BY MATCHING-ADJUSTED INDIRECT COMPARISONS

被引：0

作者：

Strand, V ^{[1
]}

McInnes, I. ^{[2
]}

Thom, H. ^{[3
]}

Hunger, M. ^{[4
]}

Lopes, N. ^{[5
]}

Gandhi, K. ^{[6
]}

Jugl, S. M. ^{[7
]}

机构：

[1] Stanford Univ, Stanford, CA 94305 USA

[2] Univ Glasgow, Glasgow, Lanark, Scotland

[3] Univ Bristol, Bristol, Avon, England

[4] Mapi Grp, Munich, Germany

[5] Novartis Biociencias SA, Sao Paulo, Brazil

[6] Novartis Pharmaceut, E Hanover, NJ USA

[7] Novartis Pharma AG, Basel, Switzerland

来源：

关键词：

D O I：

10.1016/j.jval.2017.08.2960

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PMS5

引用

页码：A935 / A936

页数：2